The global minimal residual disease testing market size was valued at USD 2.6 billion in 2025 and is projected to grow from USD 3.0 billion in 2026 to USD 7.1 billion by 2033, at a CAGR of 13.2% from 2026 to 2033. North America dominated the market with the largest revenue share of 46.4% in 2025.
This product will be delivered within 1-3 business days.
Global Minimal Residual Disease Testing Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this report, the analyst has segmented the global minimal residual testing disease market report based on cancer type, technology, end use, and region:Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Others
Cancer Outlook (Revenue, USD Million, 2021 - 2033)
- Hematological Malignancy
- Leukemia
- Lymphoma
- Solid Tumors
End use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Specialty Clinics
- Diagnostic Laboratories
- Academic and Research Institutes
- Others
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Cancer Type
1.2.3. End use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. The internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Cancer Type
1.2.3. End use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. The internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology Outlook
2.2.2. Test Type Outlook
2.2.3. Cancer Type Outlook
2.2.4. End use Outlook
2.2.5. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Technology Outlook
2.2.2. Test Type Outlook
2.2.3. Cancer Type Outlook
2.2.4. End use Outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Minimal Residual Disease Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Minimal Residual Disease Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Minimal Residual Disease Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Minimal Residual Disease Testing Market: Technology Estimates & Trend Analysis
4.1. Technology Market Share, 2025 & 2033
4.2. Segment Dashboard
4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Flow Cytometry
4.4.1.1. Flow Cytometry market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Polymerase Chain Reaction (PCR)
4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. Next Generation Sequencing (NGS)
4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
4.2. Segment Dashboard
4.3. Global Minimal Residual Disease Testing Market by Technology Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.4.1. Flow Cytometry
4.4.1.1. Flow Cytometry market estimates and forecasts 2021 to 2033 (USD Million)
4.4.2. Polymerase Chain Reaction (PCR)
4.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2021 to 2033 (USD Million)
4.4.3. Next Generation Sequencing (NGS)
4.4.3.1. Next Generation Sequencing (NGS) market estimates and forecasts 2021 to 2033 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Minimal Residual Disease Testing Market: Cancer Type Estimates & Trend Analysis
5.1. Cancer Type Market Share, 2025 & 2033
5.2. Segment Dashboard
5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Hematological Malignancy
5.4.1.1. Hematological Malignancy market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.2. Leukemia
5.4.1.2.1. Leukemia market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.3. Lymphoma
5.4.1.3.1. Lymphoma market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Solid Tumors
5.4.2.1. Solid Tumors market estimates and forecasts 2021 to 2033 (USD Million)
5.2. Segment Dashboard
5.3. Global Minimal Residual Disease Testing Market by Cancer Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.4.1. Hematological Malignancy
5.4.1.1. Hematological Malignancy market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.2. Leukemia
5.4.1.2.1. Leukemia market estimates and forecasts 2021 to 2033 (USD Million)
5.4.1.3. Lymphoma
5.4.1.3.1. Lymphoma market estimates and forecasts 2021 to 2033 (USD Million)
5.4.2. Solid Tumors
5.4.2.1. Solid Tumors market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Minimal Residual Disease Testing Market: End use Estimates & Trend Analysis
6.1. End use Market Share, 2025 & 2033
6.2. Segment Dashboard
6.3. Global Minimal Residual Disease Testing Market by End use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Hospitals and Specialty Clinics
6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Academic and Research Institutes
6.4.2.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Diagnostic Laboratories
6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. Others
6.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
6.2. Segment Dashboard
6.3. Global Minimal Residual Disease Testing Market by End use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.4.1. Hospitals and Specialty Clinics
6.4.1.1. Hospitals and Specialty Clinics market estimates and forecasts 2021 to 2033 (USD Million)
6.4.2. Academic and Research Institutes
6.4.2.1. Academic and Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
6.4.3. Diagnostic Laboratories
6.4.3.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
6.4.4. Others
6.4.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Minimal Residual Disease Testing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.5. North America
7.5.1. North America: SWOT Analysis
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Europe
7.6.1. Europe: SWOT Analysis
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific: SWOT Analysis
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Latin America
7.8.1. Latin America: SWOT Analysis
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.9. MEA
7.9.1. MEA: SWOT Analysis
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.5. North America
7.5.1. North America: SWOT Analysis
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework
7.5.4.3. Competitive scenario
7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Europe
7.6.1. Europe: SWOT Analysis
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific: SWOT Analysis
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Latin America
7.8.1. Latin America: SWOT Analysis
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.9. MEA
7.9.1. MEA: SWOT Analysis
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2025
8.3.4. Exact Sciences Corporation.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GRAIL, LLC
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Veracyte, Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Natera, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Guardant Health
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. F. Hoffmann-La Roche Ltd
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. FOUNDATION MEDICINE, INC.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. QIAGEN
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. mdxhealth.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Bio-Techne.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2025
8.3.4. Exact Sciences Corporation.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. GRAIL, LLC
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Veracyte, Inc.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Natera, Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Guardant Health
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. F. Hoffmann-La Roche Ltd
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. FOUNDATION MEDICINE, INC.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. QIAGEN
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. mdxhealth.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Bio-Techne.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Leading Market Players Anticipated to Witness Highest Growth
Table 4. Global Minimal Residual Disease Testing Market, Region, 2021 - 2033 (USD Million)
Table 5. Global Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 6. Global Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 7. Global Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 8. North America Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 9. North America Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 10. North America Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 11. North America Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 12. U.S. Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 13. U.S. Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 14. U.S. Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 15. Canada Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 16. Canada Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 17. Canada Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 18. Mexico Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 19. Mexico Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 20. Mexico Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 21. Europe Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 22. Europe Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 23. Europe Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 24. Europe Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 25. UK Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 26. UK Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 27. UK Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 28. Germany Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 29. Germany Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 30. Germany Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 31. France Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 32. France Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 33. France Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 34. Italy Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 35. Italy Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 36. Italy Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 37. Spain Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 38. Spain Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 39. Spain Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 40. Denmark Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 41. Denmark Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 42. Denmark Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 43. Sweden Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 44. Sweden Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 45. Sweden Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 46. Norway Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 47. Norway Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 48. Norway Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 49. Asia Pacific Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 50. Asia Pacific Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 51. Asia Pacific Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 52. Asia Pacific Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 53. Japan Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 54. Japan Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 55. Japan Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 56. China Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 57. China Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 58. China Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 59. India Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 60. India Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 61. India Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 62. South Korea Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 63. South Korea Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 64. South Korea Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 65. Australia Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 66. Australia Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 67. Australia Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 68. Thailand Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 69. Thailand Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 70. Thailand Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 71. Latin America Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 72. Latin America Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 73. Latin America Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 74. Latin America Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 75. Brazil Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 76. Brazil Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 77. Brazil Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 78. Argentina Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 79. Argentina Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 80. Argentina Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 81. Middle East and Africa Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 82. Middle East and Africa Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 83. Middle East and Africa Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 84. Middle East & Africa Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 85. South Africa Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 86. South Africa Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 87. South Africa Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 88. Saudi Arabia Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 89. Saudi Arabia Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 90. Saudi Arabia Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 91. UAE Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 92. UAE Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 93. UAE Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 94. Kuwait Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 95. Kuwait Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 96. Kuwait Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 2. List of Abbreviations
Table 3. Leading Market Players Anticipated to Witness Highest Growth
Table 4. Global Minimal Residual Disease Testing Market, Region, 2021 - 2033 (USD Million)
Table 5. Global Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 6. Global Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 7. Global Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 8. North America Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 9. North America Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 10. North America Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 11. North America Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 12. U.S. Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 13. U.S. Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 14. U.S. Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 15. Canada Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 16. Canada Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 17. Canada Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 18. Mexico Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 19. Mexico Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 20. Mexico Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 21. Europe Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 22. Europe Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 23. Europe Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 24. Europe Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 25. UK Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 26. UK Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 27. UK Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 28. Germany Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 29. Germany Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 30. Germany Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 31. France Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 32. France Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 33. France Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 34. Italy Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 35. Italy Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 36. Italy Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 37. Spain Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 38. Spain Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 39. Spain Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 40. Denmark Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 41. Denmark Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 42. Denmark Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 43. Sweden Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 44. Sweden Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 45. Sweden Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 46. Norway Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 47. Norway Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 48. Norway Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 49. Asia Pacific Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 50. Asia Pacific Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 51. Asia Pacific Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 52. Asia Pacific Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 53. Japan Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 54. Japan Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 55. Japan Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 56. China Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 57. China Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 58. China Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 59. India Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 60. India Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 61. India Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 62. South Korea Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 63. South Korea Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 64. South Korea Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 65. Australia Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 66. Australia Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 67. Australia Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 68. Thailand Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 69. Thailand Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 70. Thailand Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 71. Latin America Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 72. Latin America Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 73. Latin America Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 74. Latin America Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 75. Brazil Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 76. Brazil Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 77. Brazil Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 78. Argentina Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 79. Argentina Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 80. Argentina Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 81. Middle East and Africa Minimal Residual Disease Testing Market, Country, 2021 - 2033 (USD Million)
Table 82. Middle East and Africa Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 83. Middle East and Africa Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 84. Middle East & Africa Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 85. South Africa Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 86. South Africa Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 87. South Africa Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 88. Saudi Arabia Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 89. Saudi Arabia Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 90. Saudi Arabia Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 91. UAE Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 92. UAE Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 93. UAE Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
Table 94. Kuwait Minimal Residual Disease Testing Market, Technology, 2021 - 2033 (USD Million)
Table 95. Kuwait Minimal Residual Disease Testing Market, Cancer Type, 2021 - 2033 (USD Million)
Table 96. Kuwait Minimal Residual Disease Testing Market, End Use, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Minimal Residual Disease Testing: market outlook
Figure 14 Minimal Residual Disease Testing competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook.
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Minimal Residual Disease Testing driver impact
Figure 20 Minimal Residual Disease Testing restraint impact
Figure 21 Minimal Residual Disease Testing strategic initiatives analysis
Figure 22 Minimal Residual Disease Testing: Technology movement analysis
Figure 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
Figure 24 Flow Cytometry market estimates and forecast, 2021 - 2033 (USD Million)
Figure 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2021 - 2033 (USD Million)
Figure 26 Next Generation Sequencing (NGS) market estimates and forecast, 2021 - 2033 (USD Million)
Figure 27 Others market estimates and forecast, 2021 - 2033 (USD Million)
Figure 28 Minimal Residual Disease Testing: Cancer movement analysis
Figure 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
Figure 30 Hematological Malignancy market estimates and forecast, 2021 - 2033 (USD Million)
Figure 31 Leukemia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 32 Lymphoma market estimates and forecast, 2021 - 2033 (USD Million)
Figure 33 Solid Tumors market estimates and forecast, 2021 - 2033 (USD Million)
Figure 34 Minimal Residual Disease Testing: End use movement analysis
Figure 35 Minimal Residual Disease Testing: End use outlook and key takeaways
Figure 36 Hospitals & Specialty Clinics market estimates and forecast, 2021 - 2033 (USD Million)
Figure 37 Diagnostics Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Figure 38 Academic and Research Institutions market estimates and forecast, 2021 - 2033 (USD Million)
Figure 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
Figure 40 Global minimal residual disease testing market: Regional movement analysis
Figure 41 Global minimal residual disease testing market: Regional outlook and key takeaways
Figure 42 Global minimal residual disease testing market shares and leading players
Figure 43 North America
Figure 44 North America market estimates and forecast, 2021 - 2033 (USD Million)
Figure 45 U.S.
Figure 46 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
Figure 47 Canada
Figure 48 Canada market estimates and forecast, 2021 - 2033 (USD Million)
Figure 49 Mexico
Figure 50 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
Figure 51 Europe
Figure 52 Europe market estimates and forecast, 2021 - 2033 (USD Million)
Figure 53 UK
Figure 54 UK market estimates and forecast, 2021 - 2033 (USD Million)
Figure 55 Germany
Figure 56 Germany market estimates and forecast, 2021 - 2033 (USD Million)
Figure 57 France
Figure 58 France market estimates and forecast, 2021 - 2033 (USD Million)
Figure 59 Italy
Figure 60 Italy market estimates and forecast, 2021 - 2033 (USD Million)
Figure 61 Spain
Figure 62 Spain market estimates and forecast, 2021 - 2033 (USD Million)
Figure 63 Denmark
Figure 64 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
Figure 65 Sweden
Figure 66 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
Figure 67 Norway
Figure 68 Norway market estimates and forecast, 2021 - 2033 (USD Million)
Figure 69 Asia Pacific
Figure 70 Asia Pacific market estimates and forecast, 2021 - 2033 (USD Million)
Figure 71 China
Figure 72 China market estimates and forecast, 2021 - 2033 (USD Million)
Figure 73 Japan
Figure 74 Japan market estimates and forecast, 2021 - 2033 (USD Million)
Figure 75 India
Figure 76 India market estimates and forecast, 2021 - 2033 (USD Million)
Figure 77 Thailand
Figure 78 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
Figure 79 South Korea
Figure 80 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
Figure 81 Australia
Figure 82 Australia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 83 Latin America
Figure 84 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
Figure 85 Brazil
Figure 86 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
Figure 87 Argentina
Figure 88 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
Figure 89 Middle East and Africa
Figure 90 Middle East and Africa market estimates and forecast, 2021 - 2033 (USD Million)
Figure 91 South Africa
Figure 92 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
Figure 93 Saudi Arabia
Figure 94 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 95 UAE
Figure 96 UAE market estimates and forecast, 2021 - 2033 (USD Million)
Figure 97 Kuwait
Figure 98 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
Figure 99 Market share of key market players- Minimal Residual Disease Testing
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Minimal Residual Disease Testing: market outlook
Figure 14 Minimal Residual Disease Testing competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook.
Figure 17 Penetration and growth prospect mapping
Figure 18 Industry value chain analysis
Figure 19 Minimal Residual Disease Testing driver impact
Figure 20 Minimal Residual Disease Testing restraint impact
Figure 21 Minimal Residual Disease Testing strategic initiatives analysis
Figure 22 Minimal Residual Disease Testing: Technology movement analysis
Figure 23 Minimal Residual Disease Testing: Technology outlook and key takeaways
Figure 24 Flow Cytometry market estimates and forecast, 2021 - 2033 (USD Million)
Figure 25 Polymerase Chain Reaction (PCR) market estimates and forecast, 2021 - 2033 (USD Million)
Figure 26 Next Generation Sequencing (NGS) market estimates and forecast, 2021 - 2033 (USD Million)
Figure 27 Others market estimates and forecast, 2021 - 2033 (USD Million)
Figure 28 Minimal Residual Disease Testing: Cancer movement analysis
Figure 29 Minimal Residual Disease Testing: Cancer outlook and key takeaways
Figure 30 Hematological Malignancy market estimates and forecast, 2021 - 2033 (USD Million)
Figure 31 Leukemia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 32 Lymphoma market estimates and forecast, 2021 - 2033 (USD Million)
Figure 33 Solid Tumors market estimates and forecast, 2021 - 2033 (USD Million)
Figure 34 Minimal Residual Disease Testing: End use movement analysis
Figure 35 Minimal Residual Disease Testing: End use outlook and key takeaways
Figure 36 Hospitals & Specialty Clinics market estimates and forecast, 2021 - 2033 (USD Million)
Figure 37 Diagnostics Laboratories market estimates and forecast, 2021 - 2033 (USD Million)
Figure 38 Academic and Research Institutions market estimates and forecast, 2021 - 2033 (USD Million)
Figure 39 Others market estimates and forecast, 2021 - 2033 (USD Million)
Figure 40 Global minimal residual disease testing market: Regional movement analysis
Figure 41 Global minimal residual disease testing market: Regional outlook and key takeaways
Figure 42 Global minimal residual disease testing market shares and leading players
Figure 43 North America
Figure 44 North America market estimates and forecast, 2021 - 2033 (USD Million)
Figure 45 U.S.
Figure 46 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
Figure 47 Canada
Figure 48 Canada market estimates and forecast, 2021 - 2033 (USD Million)
Figure 49 Mexico
Figure 50 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
Figure 51 Europe
Figure 52 Europe market estimates and forecast, 2021 - 2033 (USD Million)
Figure 53 UK
Figure 54 UK market estimates and forecast, 2021 - 2033 (USD Million)
Figure 55 Germany
Figure 56 Germany market estimates and forecast, 2021 - 2033 (USD Million)
Figure 57 France
Figure 58 France market estimates and forecast, 2021 - 2033 (USD Million)
Figure 59 Italy
Figure 60 Italy market estimates and forecast, 2021 - 2033 (USD Million)
Figure 61 Spain
Figure 62 Spain market estimates and forecast, 2021 - 2033 (USD Million)
Figure 63 Denmark
Figure 64 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
Figure 65 Sweden
Figure 66 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
Figure 67 Norway
Figure 68 Norway market estimates and forecast, 2021 - 2033 (USD Million)
Figure 69 Asia Pacific
Figure 70 Asia Pacific market estimates and forecast, 2021 - 2033 (USD Million)
Figure 71 China
Figure 72 China market estimates and forecast, 2021 - 2033 (USD Million)
Figure 73 Japan
Figure 74 Japan market estimates and forecast, 2021 - 2033 (USD Million)
Figure 75 India
Figure 76 India market estimates and forecast, 2021 - 2033 (USD Million)
Figure 77 Thailand
Figure 78 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
Figure 79 South Korea
Figure 80 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
Figure 81 Australia
Figure 82 Australia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 83 Latin America
Figure 84 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
Figure 85 Brazil
Figure 86 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
Figure 87 Argentina
Figure 88 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
Figure 89 Middle East and Africa
Figure 90 Middle East and Africa market estimates and forecast, 2021 - 2033 (USD Million)
Figure 91 South Africa
Figure 92 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
Figure 93 Saudi Arabia
Figure 94 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
Figure 95 UAE
Figure 96 UAE market estimates and forecast, 2021 - 2033 (USD Million)
Figure 97 Kuwait
Figure 98 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
Figure 99 Market share of key market players- Minimal Residual Disease Testing
Companies Mentioned
- Exact Sciences Corporation
- GRAIL, LLC
- Veracyte, Inc.
- Natera, Inc.
- Guardant Health
- F. Hoffmann-La Roche Ltd
- FOUNDATION MEDICINE, INC.
- QIAGEN
- mdxhealth.
- Bio-Techne.
